Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
复制标题
DOI：
10.1007/s40264-021-01119-2
复制
发表时间：
2021-12
期刊：
影响因子：
4.2
通讯作者：
Koga N
中科院分区：
文献类型：
--
作者：
Sakai F;Suzuki N;Ning X;Ishida M;Usuki C;Iba K;Isogai Y;Koga N
Early discontinuation and poor adherence are common limitations of conventional preventive migraine medications that limit their long-term efficacy. Therefore, a migraine preventive medication with favorable long-term safety is warranted. This study aimed to evaluate the long-term safety and tolerability of fremanezumab for the preventive treatment of chronic or episodic migraine in Japanese patients. In this 52-week, randomized, open-label, parallel-group study, fremanezumab monthly or quarterly was administered in newly enrolled Japanese patients with chronic migraine or episodic migraine. Safety was assessed by monitoring of treatment-emergent adverse events, including injection-site reactions, laboratory and vital sign assessments. Newly enrolled patients and rollover patients from previous phase IIb/III trials who did not receive fremanezumab in this study were included in the immunogenicity testing cohort (n = 587). Efficacy outcomes included changes from baseline in the average monthly migraine days and headache days of at least moderate severity. Other efficacy outcomes included changes in disability scores. A total of 50 patients were enrolled with chronic migraine (monthly, n = 17; quarterly, n = 17) or episodic migraine (monthly, n = 8; quarterly, n = 8). The most commonly reported treatment-emergent adverse events were nasopharyngitis (64.0%) and injection-site reactions (erythema, 24.0%; induration, 10.0%; pain, 8.0%; pruritus, 6.0%). The discontinuation rate was low (4.0% from adverse events, 2.0% from a lack of efficacy) and no deaths were reported. The incidence of anti-drug antibody development was low (2.4%). Fremanezumab reduced monthly migraine days and headache days of at least moderate severity from 1 month after initial administration, and this effect was maintained with no worsening throughout 12 months. Fremanezumab also led to sustained reductions in any acute headache medication use and headache-related disability at 12 months. Fremanezumab administered monthly and quarterly was well tolerated in patients with chronic migraine and episodic migraine and led to sustained improvements in monthly migraine days and headache days of at least moderate severity throughout 12 months. ClinicalTrials.gov Identifier: NCT03303105. The online version contains supplementary material available at 10.1007/s40264-021-01119-2.
登录
查看更多内容
影响因子：
5
作者：
Blumenfeld, Andrew M.;Bloudek, Lisa M.;Lipton, Richard B.
通讯作者：
Lipton, Richard B.
DOI：
10.1007/164_2018_201
发表时间：
2019-01-01
期刊：
CALCITONIN GENE-RELATED PEPTIDE (CGRP) MECHANISMS: FOCUS ON MIGRAINE
影响因子：
--
作者：
Edvinsson, Lars
通讯作者：
Edvinsson, Lars
影响因子：
5
作者：
Woolley, J. Michael;Bonafede, Machaon M.;Lenz, Robert A.
通讯作者：
Lenz, Robert A.
影响因子：
9.9
作者：
Stewart, WF;Lipton, RB;Sawyer, J
通讯作者：
Sawyer, J
影响因子：
4.9
作者：
Hepp, Zsolt;Dodick, David W.;Devine, Emily B.
通讯作者：
Devine, Emily B.